Medications for Renal Cell Carcinoma

14 results
  • afinitor - everolimus tablet

    (Everolimus)
    Novartis Pharmaceuticals Corporation
    Afinitor treats postmenopausal women with advanced HR-positive, HER2-negative breast cancer; adults with progressive neuroendocrine tumors or advanced renal cell carcinoma; and tuberous sclerosis complex-related renal angiomyolipoma, SEGA, and partial-onset seizures (ages 2+).
  • avastin - bevacizumab injection, solution

    (Bevacizumab)
    Genentech, Inc.
    Avastin (bevacizumab) is a VEGF inhibitor used with chemotherapy to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, ovarian/fallopian tube/peritoneal cancer, and hepatocellular carcinoma. Also indicated for recurrent glioblastoma in adults.
  • bavencio - avelumab injection, solution, concentrate

    (Avelumab)
    Emd Serono, Inc.
    Bavencio (avelumab) is a PD-L1 blocking antibody indicated for metastatic Merkel cell carcinoma (adults and patients 12+), locally advanced or metastatic urothelial carcinoma (maintenance after platinum chemotherapy or following progression on platinum chemotherapy), and advanced renal cell carcinoma (first-line, with axitinib).
  • cabometyx - cabozantinib tablet

    (Cabozantinib)
    Exelixis, Inc.
    Cabometyx treats advanced renal cell carcinoma (alone or with nivolumab), hepatocellular carcinoma after sorafenib, and locally advanced or metastatic differentiated thyroid cancer or neuroendocrine tumors (pancreatic and extra-pancreatic) in adults and patients 12 and older after prior therapy.
  • inlyta - axitinib tablet, film coated

    (Axitinib)
    Pfizer Laboratories Div Pfizer Inc
    Inlyta (axitinib) treats advanced renal cell carcinoma (RCC): in combination with avelumab or pembrolizumab as first-line therapy, or as a single agent after failure of one prior systemic therapy.
  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    Keytruda is a PD-1-blocking immunotherapy indicated for numerous cancers including melanoma, non-small cell lung cancer, head and neck cancer, bladder cancer, colorectal cancer, gastric cancer, cervical cancer, renal cell carcinoma, endometrial carcinoma, triple-negative breast cancer, and other solid tumors.
  • lenvima - lenvatinib capsule

    (Lenvatinib)
    Eisai Inc.
    Lenvima treats adults with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) after prior systemic therapy.
  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
  • sutent - sunitinib malate capsule

    (Sunitinib Malate)
    Pfizer Laboratories Div Pfizer Inc
    Sutent is a kinase inhibitor for adults with gastrointestinal stromal tumor (GIST) after imatinib failure or intolerance, advanced renal cell carcinoma (RCC), adjuvant high-risk RCC after nephrectomy, and progressive unresectable locally advanced or metastatic pancreatic neuroendocrine tumors (pNET).